Sacubitril valsartan sodium tablets are decomposed into three substances, sacubitril, LBQ657 (further metabolite of sacubitril), and valsartan, with an average plasma elimination half-life of 1.43 hours, 11.48 hours, and 9.90 hours, respectively, so that the efficacy of this product lasts for about 24 hours after a single dose. Sacubitril valsartan sodium contains the enkephalinase inhibitor sacubitril and the angiotensin receptor antagonist valsartan, both of which have blood pressure-lowering effects, and the combination of the two drugs can be used in patients with chronic heart failure who have a low ejection fraction, which reduces the risk of death from cardiovascular events and the risk of hospitalization for heart failure. The administration of this product can lead to adverse reactions such as hypotension, angioedema, hyperkalemia, and renal impairment. Note that it is contraindicated in patients with angioedema, cholestasis, cirrhosis, and severe hepatic impairment. Special populations: middle and late pregnant women should be prohibited, lactating women should stop breastfeeding. children under 18 years of age, the safety of the drug is not clear. The safety of the drug for children under 18 years of age is not clear. Patients should use the drug under the guidance of a professional physician and strictly comply with medical advice.